VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 468 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2015. The put-call ratio across all filers is 0.90 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $32,000 | -15.8% | 179 | +5.9% | 0.00% | 0.0% |
| Q2 2015 | $38,000 | -64.8% | 169 | -68.9% | 0.00% | -66.7% |
| Q1 2015 | $108,000 | +260.0% | 543 | +158.6% | 0.01% | +200.0% |
| Q4 2014 | $30,000 | 0.0% | 210 | -7.5% | 0.00% | 0.0% |
| Q3 2014 | $30,000 | +15.4% | 227 | +8.1% | 0.00% | 0.0% |
| Q2 2014 | $26,000 | +30.0% | 210 | +38.2% | 0.00% | 0.0% |
| Q1 2014 | $20,000 | +11.1% | 152 | -3.2% | 0.00% | +100.0% |
| Q4 2013 | $18,000 | +20.0% | 157 | +12.9% | 0.00% | 0.0% |
| Q3 2013 | $15,000 | 0.0% | 139 | -18.2% | 0.00% | -50.0% |
| Q2 2013 | $15,000 | 0.0% | 170 | -17.1% | 0.00% | 0.0% |
| Q1 2013 | $15,000 | +7.1% | 205 | -35.5% | 0.00% | 0.0% |
| Q2 2012 | $14,000 | -6.7% | 318 | +12.0% | 0.00% | 0.0% |
| Q1 2012 | $15,000 | +7.1% | 284 | -4.1% | 0.00% | 0.0% |
| Q4 2011 | $14,000 | +40.0% | 296 | +12.5% | 0.00% | +100.0% |
| Q3 2011 | $10,000 | – | 263 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |